Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Bendamustine + Rituximab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bendamustine | Treanda | Ribomustin|SyB L-0501|SDX-105 | Chemotherapy - Alkylating 16 | Treanda (bendamustine) is an alkylating agent with unique mechanisms, resulting in increased DNA damage and base-excision DNA repair pathway induction, and potentially leading to decreased growth of tumors, including those resistant to other alkylating agents (PMID: 18172283, PMID: 19117340, PMID: 19224851). Treanda (bendamustine) is FDA approved for use in chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma (FDA.gov). |
Rituximab | Rituxan | IDEC-C2B8|MabThera | CD20 Antibody 18 | Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 loss | mantle cell lymphoma | no benefit | Bendamustine + Rituximab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma with TP53 loss, as well as a CCND1 translocation, had no response to combined Rituxan (rituximab) and Treanda (bendamustine) therapy, and had a doubling of white blood cells during two cycles of treatment (PMID: 30559058). | 30559058 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04666038 | Phase III | Idelalisib + Rituximab Pirtobrutinib Bendamustine + Rituximab | Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 16 |
NCT05371093 | Phase III | axicabtagene ciloleucel Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Fludarabine Bendamustine + Rituximab Lenalidomide + Rituximab | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22) | Recruiting | USA | ITA | FRA | 0 |
NCT01974440 | Phase III | Ibrutinib Bendamustine + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | Active, not recruiting | USA | FRA | ESP | DEU | BEL | 14 |
NCT02626455 | Phase III | Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 28 |
NCT02972840 | Phase III | Bendamustine + Rituximab Acalabrutinib + Bendamustine + Rituximab | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 20 |
NCT01216683 | Phase II | Bendamustine + Rituximab Bortezomib Lenalidomide | Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma | Completed | USA | 0 |
NCT02257567 | Phase Ib/II | Bendamustine + Rituximab Polatuzumab vedotin-piiq Obinutuzumab | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | Completed | USA | ITA | FRA | ESP | DEU | CAN | 7 |
NCT02763319 | Phase II | Bendamustine + Tafasitamab-cxix Bendamustine + Rituximab | A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 16 |
NCT04628494 | Phase III | Gemcitabine + Oxaliplatin + Rituximab Epcoritamab-bysp Bendamustine + Rituximab | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 17 |
NCT03836261 | Phase III | Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 22 |
NCT01059786 | Phase II | Bendamustine + Rituximab Pentostatin + Rituximab | Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | Recruiting | USA | 0 |
NCT01732926 | Phase III | Idelalisib Bendamustine + Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | ITA | FRA | ESP | DEU | CAN | 9 |
NCT05023980 | Phase III | Pirtobrutinib Bendamustine + Rituximab | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313) | Recruiting | USA | ITA | FRA | ESP | AUT | 16 |
NCT02576275 | Phase III | Bendamustine + Rituximab Duvelisib | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | Withdrawn | USA | 0 |
NCT02951156 | Phase III | Avelumab + Azacitidine + Utomilumab Avelumab + Rituximab + Utomilumab Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab Avelumab + Bendamustine + Rituximab | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | Terminated | USA | ITA | ESP | BEL | 4 |
NCT04002297 | Phase III | Rituximab + Zanubrutinib Bendamustine + Rituximab | Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Patients With Untreated Mantle Cell Lymphoma | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 11 |
NCT03609593 | Phase II | Rituximab Bendamustine + Rituximab Venetoclax | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT02187861 | Phase II | Bendamustine + Rituximab Bendamustine + Rituximab + Venetoclax Rituximab + Venetoclax | A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma | Completed | USA | ITA | FRA | DEU | CAN | BEL | 2 |
NCT03336333 | Phase III | Venetoclax + Zanubrutinib Zanubrutinib Bendamustine + Rituximab | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | AUT | 8 |
NCT04285567 | Phase III | Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO) | Recruiting | USA | ITA | FRA | ESP | 1 |
NCT05139017 | Phase II | Bendamustine + Rituximab + VLS-101 Gemcitabine + Oxaliplatin + Rituximab + VLS-101 Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Recruiting | USA | ITA | FRA | CAN | 3 |
NCT05848765 | Phase II | Bendamustine + Obinutuzumab Epcoritamab-bysp + Lenalidomide Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Lenalidomide + Rituximab | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT) | Not yet recruiting | 1 |